Veeva Systems R&D increased by 3.6% to $198.79M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 9.5%, from $181.53M to $198.79M. Over 4 years (FY 2022 to FY 2026), R&D shows an upward trend with a 19.0% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $83.23M | $94.90M | $98.64M | $105.28M | $113.48M | $134.01M | $130.26M | $142.54M | $146.96M | $157.23M | $161.28M | $163.57M | $162.71M | $176.43M | $172.41M | $181.53M | $184.03M | $192.68M | $191.88M | $198.79M |
| QoQ Change | — | +14.0% | +3.9% | +6.7% | +7.8% | +18.1% | -2.8% | +9.4% | +3.1% | +7.0% | +2.6% | +1.4% | -0.5% | +8.4% | -2.3% | +5.3% | +1.4% | +4.7% | -0.4% | +3.6% |
| YoY Change | — | — | — | — | +36.3% | +41.2% | +32.1% | +35.4% | +29.5% | +17.3% | +23.8% | +14.8% | +10.7% | +12.2% | +6.9% | +11.0% | +13.1% | +9.2% | +11.3% | +9.5% |
| Segment | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|
| Reportable Segment | $136.08M | $139.29M | $139.09M | $148.03M |
| Total | $184.03M | $192.68M | $191.88M | $198.79M |